ClinicalTrials.gov
public full text
Public Domain
A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia
The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022. Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R WM will be evaluated in approximately 44 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Does early disease progression predicts survival after first line-treatment of Waldenström macroglobulinemia?#378090
- Alemtuzumab in Treating Patients With Waldenstrom's Macroglobulinemia#863121
- Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia#903366
- The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM#871644
- Treatment preferences in Waldenström macroglobulinemia: an international discrete choice experiment in 1455 patients.#823433
Record · ID 865705
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive